MYD88 gene polymorphisms in patients with chronic lymphoid leukemia

Leukemia is a type of cancer that manifests itself with the more than usual proliferation of blood cells, especially white blood cells, and affects the blood production system in the body. Leukemias are classified as acute or chronic and according to the spread and developmental characteristics of the tumor. In chronic lymphocyte leukemia (CLL), cancer cells are found in the bone marrow, blood, and lymph nodes. Therefore, in this study, the effects of polymorphisms occurring in MYD88 gene of CLL patients has been researched. For this purpose, 100 patients diagnosed with CLL and 70 healthy individuals without a history of cancer were included in the study as a control group. DNA was isolated from CLL patients and control groups. Polymorphisms in MYD88 (L265p T / C) promoter regions were studied by RT-PCR. Genotype and allele frequencies were calculated directly. The statistical significance of genotypic distributions between CLL patients and control groups was evaluated by Z Ratios test and Fisher's Exact test. For MYD88 L265p T / C region in 100 CLL patients, 95 wild type TT, 3 TC and 5 mutant type CC genotypes were detected. There was no statistically significant difference between CLL patients and control groups in MYD88 L265p T / C region (p> 0.05). According to the allele frequencies of the region, it was determined as 0.965 and 0.0065 for T and C, respectively. According to Fisher's Exact results, it was calculated as 0.078 for TT, 0.078 for TC and 0.269 for Mutant, respectively. MYD88 genotype frequencies of the patients included in the study were not statistically correlated with CLL patients. Therefore, if the research is done again; It should be done by adding more samples to the numbers of CLL patients. Key Words: CLL, MYD88, Polymorphism, Real-Time PCR